Cost of Merck COVID-19 pill: How treatment compares to vaccines, monoclonal antibodies

Norge Nyheter Nyheter

Cost of Merck COVID-19 pill: How treatment compares to vaccines, monoclonal antibodies
Norge Siste Nytt,Norge Overskrifter
  • 📰 Newsweek
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 52%

Merck's COVID-19 pill showed it prevented hospitalization or death in unvaccinated adults by 50 percent.

's vaccine cost the government about $40, Moderna's cost about $30 for full vaccination, and Johnson & Johnson's one-dose vaccination was only about $10 per dose, according to the Congressional Research Service.

Merck's oral antiviral pill is less expensive than monoclonal antibody treatments but more expensive than getting vaccinated against COVID-19. Above, employees walk past a Merck sign in front of the company's building on October 2, 2013, in Summit, New Jersey.More than 180 million Americans are fully vaccinated against COVID-19 but despite about 65 percent of the country's population being inoculated, hospitals continue to be overwhelmed.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

Newsweek /  🏆 468. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Covid-19: NHS Covid passes, and lockdown lifted in SydneyCovid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
Les mer »

Merck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravirMerck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravirMerck said it is seeking FDA emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.
Les mer »

Merck asks the FDA to authorize use of its promising COVID-19 pillMerck asks the FDA to authorize use of its promising COVID-19 pillDrugmaker Merck has asked U.S. regulators to authorize its promising pill protecting against COVID-19, setting the stage for a decision within weeks.
Les mer »

Merck Seeks FDA Authorization for Antiviral COVID-19 PillMerck Seeks FDA Authorization for Antiviral COVID-19 PillDrugmaker Merck announced Monday that it submitted an application to the FDA for emergency use authorization of molnupiravir, an experimental antiviral COVID-19 treatment.
Les mer »

Where America's cases, hospitalizations, deaths stand 19 months into the COVID-19 pandemicWhere America's cases, hospitalizations, deaths stand 19 months into the COVID-19 pandemicAlthough hospitalizations nationwide have been trending downward since September, more than 40,000 people remain hospitalized with COVID-19.
Les mer »



Render Time: 2025-03-10 22:16:28